

Electronic Acknowledgement Receipt

EFS ID:	6217384
Application Number:	10585772
International Application Number:	
Confirmation Number:	4680
Title of Invention:	Antisense Oligonucleotides Directed to Ribonucleotide Reductase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer
First Named Inventor/Applicant Name:	Aiping H. Young
Customer Number:	21559
Filer:	Forrester J. Liddle/Heather Bellone
Filer Authorized By:	Forrester J. Liddle
Attorney Docket Number:	50120/008001
Receipt Date:	14-OCT-2009
Filing Date:	13-NOV-2007
Time Stamp:	14:59:15
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Hananla_Am_J_Med_1995.PDF	2325368 301118be515e11b1e6998d54586a767ee 65b4	no	16

Warnings:

Information:

2	NPL Documents	Hards_J_Cell_Physiol_1981. PDF	1202586 16a8f6e14d829f1e02a779f8ab81bcb705c5f1d84ab	no	11
Warnings:					
Information:					
3	NPL Documents	Holmlund_Ann_NY_Acad_Sci_2003.PDF	542792 6f55631bcb968b8e548b1d6b7ef8418f58099	no	8
Warnings:					
Information:					
4	NPL Documents	Huang_Cancer_Res_1997.PDF	770018 bd72a050e94607895072c55873c472051325J89	no	6
Warnings:					
Information:					
5	NPL Documents	Hurta_J_Biol_Chem_1991.PDF	750493 af7d5863ba8308b6c20bb1c51b795b81120c81010	no	4
Warnings:					
Information:					
6	NPL Documents	Hurta_J_Biol_Chem_1992.PDF	1165154 d039ee709ce4815e0d54b1a7e8b1ee0449160e9	no	6
Warnings:					
Information:					
7	NPL Documents	Hurta_J_Cell_Biochem_1995. PDF	1750169 12d4ae1c2b15036641d351a742edf138abb944f	no	14
Warnings:					
Information:					
8	NPL Documents	Hurta_J_Cell_Physiol_1994.PDF	1420237 48cbbeb6dad9ce691abdc7747b359c1959a9052	no	11
Warnings:					
Information:					
9	NPL Documents	Jelinek_Mol_Cell_Biol_1994. PDF	1061979 c5ab7d7db7d412d5d56a2766a8d94c022e0159898	no	7
Warnings:					
Information:					
10	NPL Documents	Kohn_J_Natl_Cancer_Inst_1996.PDF	284744 64098b3c3a119c28a93ac953105ca8944c092	no	2
Warnings:					
Information:					

11	NPL Documents	Koong_Cancer_Res_1994.PDF	975019 025db4d779a0b07271b2c1b2c092b0d55f9ee	no	7
Warnings:					
Information:					
12	NPL Documents	Kuschak_Oncogene_2002.PDF	1826715 80a12809a9c5d41111992bc091b0b15c54530c7	no	12
Warnings:					
Information:					
13	NPL Documents	Leevers_Nature_1994.PDF	658957 bdc10c7371b0c103ad4b7070ef0c14229f67d	no	4
Warnings:					
Information:					
14	NPL Documents	LefebvreHellencourt_Eur_Cytokine_Netw_1995.PDF	1358952 fe00c7fb2776c5d57c21601d51ad14019481e02	no	13
Warnings:					
Information:					
15	NPL Documents	Lenormand_J_Biol_Chem_1996.PDF	1124461 4b7ea1244212c49679b1671381700f9b7119c275	no	7
Warnings:					
Information:					
16	NPL Documents	Lewis_J_Cell_Physiol_1978.PDF	1113313 a073e07c09294803780076e99199a401b55d2	no	11
Warnings:					
Information:					
17	NPL Documents	Lewis_J_Cell_Physiol_1978_Volume_94.PDF	1123950 62b769ebc71624289a9c65810b4b467041cc0d	no	12
Warnings:					
Information:					
18	NPL Documents	Mann_Cancer_Res_1988.PDF	848628 64e07a502bc1b9f1a9c025f36399236c997e0c	no	6
Warnings:					
Information:					
19	NPL Documents	Jensen_Proc_Natl_Acad_Sci_USA_1994.PDF	1822319 2975f3ca08a0f803329a6c6d0f998c3ab4179000	no	5
Warnings:					
Information:					

20	NPL Documents	McClarty_Biochemistry_1987. PDF	1560071 a78dec544dd6fa1096dc209188e55285 bc0f6	no	8
Warnings:					
Information:					
21	NPL Documents	McClarty_Biochemistry_1988. PDF	1488883 6927dc75d24085ce912d87a8b7cd2ae8803 cbe5d	no	8
Warnings:					
Information:					
22	NPL Documents	McClarty_J_Biol_Chem_1990. PDF	2440059 d4ec98d2ca23c8cb74f02ce998c55c011c7 b55d	no	9
Warnings:					
Information:					
23	NPL Documents	Morgan_Adv_CancerRes_1997. PDF	2121520 790dd1346209cdebdc7ac08ac1cc2d2738 75e8	no	25
Warnings:					
Information:					
24	NPL Documents	Motzer_J_Clin_Oncol_2002. PDF	857933 f9b79840552bb07d3dec547407aad759c987 b3ca0	no	8
Warnings:					
Information:					
25	NPL Documents	Negrier_Ann_Oncol_2002.PDF	768154 2980b59bbac2c5f9081c1193b50676efdc0 1782	no	9
Warnings:					
Information:					
26	NPL Documents	Negrier_J_Clin_Oncol_2000. PDF	787412 e146bdc4226db664788ac76519c8cd3a1743 e83c	no	7
Warnings:					
Information:					
27	NPL Documents	Parker_Nucleic_Acids_Res_199 1.PDF	124370 e15c216d24bc0d8139fb6d1761d3ad75d02 ed3c	no	1
Warnings:					
Information:					
28	NPL Documents	Pavlick_Exp_Opin_Inves_Drugs _2003.PDF	1939122 84dc798b396fb23667519525a8192191a eeb65	no	14
Warnings:					
Information:					

29	NPL Documents	Piepmeyer_Cancer_Res_1996.PDF	395859 1c2f8a964f3dbdd6ba73dbd890060501b368a5	no	3
Warnings:					
Information:					
30	NPL Documents	Potsch_Mol_Pharmacol_1994.PDF	697461 c3e9493882b3c5c9a8a200a2945e07ad1047	no	5
Warnings:					
Information:					
31	NPL Documents	Price_ProcNatI_Acad_Sci_USA_1987.PDF	940277 0fe0838b3b3b4048e384f3e09554d83e5041980ec	no	5
Warnings:					
Information:					
32	NPL Documents	Pyrhonen_J_Clin_Oncol_1999.PDF	932532 48065e94526d03b6b7875e0e06dc209f8dc31ef16	no	9
Warnings:					
Information:					
33	NPL Documents	Qui_Nature_1995.PDF	469139 e38d2ac3dbd4f10954235073403a50f204e303a	no	3
Warnings:					
Information:					
34	NPL Documents	Recchia_Proc_European_Society_of_Med_Oncol_Congress_2004.PDF	188697 ac3b175d17cdf5a3b88ac6526468dad3a301465	no	1
Warnings:					
Information:					
35	NPL Documents	Reichard_Science_1993.PDF	881286 28f7d0c1f685d6d2e3ba0b06ff004bc5da3a04d31	no	5
Warnings:					
Information:					
36	NPL Documents	Rojanasakul_Adv_Drug_Deliv_Rev_1996.PDF	1890966 d38c2f44304a0d4e09d17399ca0db0f4d4d49d	no	17
Warnings:					
Information:					
37	NPL Documents	Rosolen_Cancer_Res_1990.PDF	1077988 b4db733268561b4ff23379ba3dbb53742938a5	no	7
Warnings:					
Information:					

38	NPL Documents	Roy_Biochemistry_1995.PDF	1481291 6d11567c5b6ee4d818a781a6f6ca2d810209d19	no	8
Warnings:					
Information:					
39	NPL Documents	Saeki_Int_J_Oncol_1995.PDF	1228196 71ebd695d80a39c5aaf7a7b79ca20c3c1d7d8a1c4	no	7
Warnings:					
Information:					
40	NPL Documents	Salem_FEBS_Lett_1993.PDF	559451 a1c3d89bc7bf172747f8130494dc39215baa2	no	3
Warnings:					
Information:					
41	NPL Documents	Santarossa_Eur_J_Cancer_1995.PDF	161130 4ef0113e178bcc1bf102909230dc5c0a2d78b	no	1
Warnings:					
Information:					
42	NPL Documents	Scanlon_FASEB_J_1995.PDF	1348762 b1d47cc6508a0ee0282623dc5c0d550e798c	no	9
Warnings:					
Information:					
43	NPL Documents	Seheult_Abstracts_of_the_General_Meeting_of_the_Am_Soc_for_Microbiol_2002.PDF	85403 26a5a2466a792548230e08118b5a677ee420095c0	no	1
Warnings:					
Information:					
44	NPL Documents	Shaw_Nucleic_Acids_Res_1991.PDF	451393 ce3c25a7c595d8bc2099b0d1686d719ee7cc	no	4
Warnings:					
Information:					
45	NPL Documents	Slabaugh_J_Biol_Chem_1993.PDF	1260326 390957abb49d0919bc3205ce74b20bf02994c5576	no	8
Warnings:					
Information:					
46	NPL Documents	Standart_Genes_Dev_1990.PDF	1462516 0b70858031a81a5c6b6c41973ba99426561b1e	no	12
Warnings:					
Information:					

47	NPL Documents	Sun_Gene_Therapy_2001.PDF	1122021 2a8047a230c18e5a6d41286a70b56ca 0f5c	no	8
Warnings:					
Information:					
48	NPL Documents	Szekeres_Cancer_Chemother_... Pharmacol_1994.PDF	560633 804e0e0c4dc6927a089ca27e101de0079 3c3d	no	4
Warnings:					
Information:					
49	NPL Documents	Takeda_Life_Science_1981.PDF	696870 8ea35e7f118f9f7664bb3c35c12ac0411-cf 8f0e	no	8
Warnings:					
Information:					
50	NPL Documents	Thelander_EMBO_J_1989.PDF	650447 80e9613c1568bdcabbe74148edc831541 ee0ee	no	5
Warnings:					
Information:					
51	NPL Documents	Thelander_J_Biol_Chem_1980. PDF	1100096 6c99328249936d1131092816dd3d270d7 c005	no	7
Warnings:					
Information:					
52	NPL Documents	Thelander_J_Biol_Chem_1985. PDF	764593 a876515ce69476ddc1c36c9a3896c585c7 05e	no	5
Warnings:					
Information:					
53	NPL Documents	Thelander_Mol_Cell_Biol_1986. PDF	1786560 d9d7e75a98b88b86c197844b86541af02 53c4b	no	10
Warnings:					
Information:					
54	NPL Documents	Tonin_Cytogenet_Cell_Genet_... 1987.PDF	944219 e4ed756060e3d81e73262ef59696e3d4 5a3d	no	7
Warnings:					
Information:					
55	NPL Documents	Tourani_J_Clin_Oncol_2003. PDF	1040778 8d5fadb6301746cd0f6a603993b2e74f79 a8a	no	8
Warnings:					
Information:					

56	NPL Documents	Van_Herpen_Br_J_Cancer_2000.PDF	623270 90862a3487c0322b6d6a6d6e51d235f7b1b	no	5
Warnings:					
Information:					
57	NPL Documents	Wagner_Nature_1994.PDF	518731 b5d017ad9eb7271313d1593779981553f192835	no	3
Warnings:					
Information:					
58	NPL Documents	Stubbe_Ann_Rev_Biochem_1989.PDF	2432273 2bb29ed0bAcdf236c5a5401886962610310276	no	31
Warnings:					
Information:					
59	NPL Documents	Gura_Science_1997.PDF	434997 02d9100e5bbf14366bf7dc3ef1ee8cb975d0b0	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			62401539		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.					
<u>New Applications Under 35 U.S.C. 111</u>					
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.					
<u>National Stage of an International Application under 35 U.S.C. 371</u>					
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.					
<u>New International Application Filed with the USPTO as a Receiving Office</u>					
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					